Pacira BioSciences (PCRX) Operating Leases (2019 - 2026)

Pacira BioSciences' Operating Leases history runs 8 years deep, the most recent figure standing at $33.7 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 22.83% year-over-year to $33.7 million in Q1 2026; TTM through Mar 2026 was $33.7 million, a 22.83% decrease from a year earlier, with the FY2025 full-year figure at $36.2 million, down 18.97% from the prior year.
• Operating Leases retreated to $33.7 million in Q1 2026 per PCRX's latest filing, from $36.2 million in the prior quarter.
• Across five years, Operating Leases topped out at $77.7 million in Q1 2022 and bottomed at $33.7 million in Q1 2026.
• The 5-year median for Operating Leases is $54.8 million (2023), against an average of $54.4 million.
• Across the five-year window, Operating Leases grew 11.57% in 2022 and tumbled 31.94% in 2025, its largest moves.
• Year by year, Operating Leases stood at $64.8 million in 2022, then fell by 15.43% to $54.8 million in 2023, then decreased by 18.54% to $44.6 million in 2024, then slipped by 18.97% to $36.2 million in 2025, then retreated by 6.83% to $33.7 million in 2026.
• Per Business Quant, the three latest PCRX Operating Leases figures stand at $33.7 million (Q1 2026), $36.2 million (Q4 2025), and $38.8 million (Q3 2025).